On August 28, Junshengtai Medicine-B (02511.HK) announced its interim performance. In the first half of 2024, other income and revenue amounted to RMB 38.3 million, an increase of 68.7% year-on-year. Research and development costs amounted to RMB 0.202 billion, an increase of 68.2%. The increase was mainly due to an increase in third-party contracting expenses of approximately RMB 70.8 million and an increase in expenses under the long-term employee incentive plan of approximately RMB 12 million. The loss amounted to RMB 0.211 billion, compared to RMB 5.497 billion in the first half of 2023.

As of June 30, 2024, the group's current assets amounted to RMB 0.594 billion, including RMB 0.392 billion in cash and bank balances, and RMB 0.202 billion in other current assets.

It is reported that the group is a biopharmaceutical company, focusing on the discovery, development, and commercialization of multi-functional and multi-target therapies for metabolic and digestive system diseases. The group has independently developed a product pipeline consisting of 5 candidate products, covering 8 indications for metabolic and digestive system diseases. Among them, 2 candidate products are in clinical stage, involving 5 indications. HTD1801 (berberine hydrochloride) is a new molecular entity that acts as an intestinal and liver anti-inflammatory and metabolic regulator, targeting multiple pathways that are critically important in human metabolic processes, including those related to metabolic and digestive system diseases. Other candidate products include HTD4010, HTD1804, HTD1805, and HTD2802.